Trials / Completed
CompletedNCT00478231
Multicenter, Safety Study Of Maraviroc
A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc | Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc. |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2010-08-01
- Completion
- 2010-09-01
- First posted
- 2007-05-24
- Last updated
- 2011-09-09
- Results posted
- 2011-08-08
Locations
16 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00478231. Inclusion in this directory is not an endorsement.